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Background: Studies evaluating CYP2C19*2 and ABCB1-C3435T polymorphisms have shown
conflicting results. We performed this meta-analysis to evaluate role of clinical testing for
these polymorphisms in CAD patients on clopidogrel.
Methods: 19,601 patients from 14 trials were analyzed. The endpoints were major adverse
cardiovascular events (MACE), cardiovascular (CV) death, stent thrombosis (ST), myocar-
dial infarction (MI), stroke and major bleeding. Combined relative risks (RR) with 95%
confidence intervals (CI) were computed for each outcome by using standard methods of
meta-analysis and test parameters were computed.
Results: CYP2C19*2 polymorphism was associated with higher risk of MACE [RR: 1.28, CI:
1.06e1.54; p¼ 0.009], CV death [RR: 3.21, CI: 1.65e6.23; p¼ 0.001], MI [RR: 1.36, CI: 1.12e1.65;
p¼ 0.002], ST [RR: 2.41, CI: 1.69e3.41; p< 0.001]. No difference was seen in major bleeding
events [RR: 1.02, CI: 0.86e1.20; p¼ 0.83]. Subgroup analysis showed similar results for
elective PCI [RR: 1.34, CI: 1.01e1.76; p¼ 0.03], and PCI with DES [RR: 1.53, CI: 1.029e1.269;
p¼ 0.03]. CYP2C19*2 polymorphism has very low sensitivity (28e58%), specificity (71e73%),
positive predictive value (3e10%) but good negative predictive value (92e99%). ABCB1-
C3435T polymorphism analysis revealed similar MACE [RR: 1.13, CI: 0.99e1.29; p¼ 0.06],
ST [RR: 0.88, CI: 0.52e1.47; p¼ 0.63] and major bleeding [RR: 1.04, CI: 0.87e1.25; p¼ 0.62] in
both groups.
Conclusion: In CAD patients on clopidogrel therapy, CYP2C19*2 polymorphism is associated
with significantly increased adverse cardiovascular events. However, due to the low
positive predictive value, routine genetic testing cannot be recommended at present.
Copyright ª 2012, Cardiological Society of India. All rights reserved.1. Background acute coronary syndrome (ACS).1 In Percutaneous CoronaryDual antiplatelet therapy of aspirin and clopidogrel is now
established as a standard of care for patients undergoing
percutaneous coronary intervention (PCI) or patient withom (M. Singh).
2012, Cardiological SocietIntervention in the Clopidogrel in Unstable angina to prevent
Recurrent Events (PCI-CURE) study, dual antiplatelet therapy
(DAPT) in patients with non-ST elevation myocardial infarc-
tion (NSTEMI) lead to 31% reduction in cardiovascular death ory of India. All rights reserved.
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i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1e3 5 2342myocardial infarction (MI).2 Similarly, in ClOpidogrel and
Metoprolol in Myocardial Infarction Trial (COMMIT), DAPT in
patients with ST elevation myocardial infarction (STEMI) was
shown to reduce all causemortality, andmajor cardiovascular
events (MACE) including reinfarction.3
However, despite the use of DAPT, nearly 10% patients still
experience recurrent MACE.4e7 Persistent occurrence of MACE
during DAPT may be partially explained by inter-individual
variability of clopidogrel response, especially in patients
undergoing PCI.8e10 One of the postulated non-modifiable
factors for variability of response can be attributed to phar-
macogenetics of clopidogrel metabolism.
Clopidogrel is a prodrug that requires to be converted in to
active metabolites to irreversibly bind to the P2Y12 receptor.
Clopidogrel metabolism is a two steps process dependent on
cytochrome P450 (CYP), with contributions from the isoen-
zymes like: CYP2C19, CYP3A4 or CYP3A5, CYP2C9, CYP1A2,
and CYP2B6.11e13 CYP2C19 is a key enzyme in this activation
process. There are at least 9 LoF alleles in CYP2C19 gene: *2e*8
null-functioning, *9e*10 decreased functioning. The presence
of carriers of the loss-of-function alleles of CYP2C19 poly-
morphism is associated with clopidogrel non-responsiveness
in healthy people and in patients with coronary artery disease
(CAD).14e16 In addition to CYP2C19 polymorphism, variations
in the gene regulating clopidogrel absorption and efflux by
encoding the P-glycoprotein a multi drug resistant-1 efflux
transporter (called ABCB1),17 might also affect the rate of
clinical events during treatment. According to ACC/AHA
guidelines, current evidence base is insufficient to recom-
mend either routine genetic or platelet function testing at the
present time. There is no information that routine testing
improves outcome in large sub-groups of patients and hence
is not currently recommended.18Potentially relevant studies
identified and screened for
retrieval (n = 107)
Not clinical trials
(n = 67)
Clinical trials
(n = 40)
Total clinical trials
(n = 21)
Studies for final analysis
(n = 14)
Did not meet inclusion
criteria (n = 19)
• No clinical outcomes: n = 3
• Different adjunctive
  medications: n = 2
•  Different genotype: n = 1
• Data not extractable: n = 1
Trial excluded (n = 7)
Fig. 1 e Study selection process for CYP2C19*2
polymorphism.
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Table 2 e Heterogeneity results for individual study outcomes and subgroup outcomes.
Q-value df (Q) P-value I-squared Result Publication bias
(Funnel plots)
All studies of CYP219*2
MACE 32.9 13 0.002 60.5 Heterogenic None
CV deaths 2.0 4 0.730 0.0 Homogenic None
MI 6.6 5 0.250 24.5 Homogenic Possible
Stroke 1.7 2 0.425 0.0 Homogenic None
Major bleeding 1.9 2 0.393 0.0 Homogenic None
Stent thrombosis 7.3 5 0.199 31.5 Homogenic Possible
All studies ABCB1
MACE 7.2 2 0.027 72.4 Heterogenic None
Stent thrombosis 0.2 1 0.692 0.0 Homogenic Cannot be evaluate e
only 2 studies
Major bleeding 1.2 1 0.269 18.0 Homogenic Cannot be evaluate e
only 2 studies
Elective PCI sub-groups of CYP219*2
MACE 5.6 3 0.136 46.0 Homogenic No
ACS sub-groups of CYP219*2
MACE 20.6 6 0.002 70.9 Heterogenic No
CV deaths 1.4 2 0.493 0.0 Homogenic No
MI 4.7 2 0.095 57.4 Heterogenic No
Major bleeding 1.9 2 0.393 0.0 Homogenic No
Stent thrombosis 6.2 3 0.102 51.7 Homogenic Possible
DES sub-groups of CYP219*2
MACE 11.5 4 0.022 65.1 Heterogenic No
MI 6.4 2 0.041 68.6 Heterogenic Possible
Stent thrombosis 1.2 2 0.555 0.0 Homogenic Possible
[PCI¼ Percutaneous Coronary Interventions, ACS¼Acute Coronary Syndrome, CAD¼Coronary artery diseases, MACE¼Major Adverse
Cardiovascular Event, CV¼Cardiovascular and DES¼Drug Eluting Stent.]
i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 3 4 1e3 5 2 343Individual studies evaluating role of CYP2C19*2 poly-
morphism and ABCB1-C3435T polymorphism have yielded
mix results. Therefore we performed pooled analysis of
prospective studies comparing clinical outcomes in patients
with CYP2C19*2 and ABCB1 polymorphism on clopidogrel
therapy to evaluate association and role of clinical testing for
these polymorphisms in CAD patients on clopidogrel.2. Methods
We performed this review in accordance with the Quality of
Reporting of Meta-analysis (QUOROM) statement and the
Consolidated Standards of Reporting Trials (CONSORT) Group
recommendations.19 A protocol was prospectively developed,
detailing the objectives, criteria for study selection and
approach to assessing the study quality, primary outcome and
methodology.
2.1. Literature search
We searched the National Library of Medicine Pub Med,
National Institutes of Health clinical trials registry and the
Cochrane Central Register of Controlled Trials for prospective
studies of CAD patients on clopidogrel treatment comparing
clinical outcomes based on CYP2C19*2 and ABCB1 poly-
morphism. Selection process was similar both polymorphism.
Wealso searched Internet-based sourcesof informationon theresults of clinical trials in cardiology (www.cardiosource.com/
clinicaltrials,www.theheart.org,www.clinicaltrialresults.com
andwww.tctmd.com), as well as conference proceedings from
meetings of the American College of Cardiology, the American
Heart Association, and the European Society of Cardiology.
Searches were restricted to the period from January 2000
through May 2011. The key words used for search were: coro-
nary artery disease, acute coronary syndrome, percutaneous coro-
nary interventions, STEMI,NSTEMI,UnstableAngina, stable angina,
clopidogrel, prasugrel, ticagrelor, CYP2C19, CYP3A4 or CYP3A5,
CYP2C9, CYP1A2, and CYP2B6, ABCB1.
2.2. Study selection
Two independent authors reviewed all titles and abstracts
from the results of our computerized search. We also went
into the related links of all relevant articles. In addition to our
computerized search, wemanually reviewed the reference list
of all retrieved articles to complete our search. Study selection
process is outlined in Fig. 1.
2.3. Inclusion criteria
We included in our analysis the results of randomized clinical
trials or post hoc analysis of randomized control trial that
compared clinical outcomes of patients with and without
CYP2C19*2 and ABCB1 polymorphism in CAD patients on
clopidogrel treatment.
i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1e3 5 2344All studies had to meet all the following criteria to be
included in the analysis:
1. Randomized controlled trial or post hoc analysis of
randomized controlled trials.
2. Include patients with coronary artery diseases mainly
undergoing PCI.
3. Compare CYP2C19*2 carrier (variant) versus non-carrier
(normal) and ABCB1 polymorphism (CT/TT) versus normal
(CC).
4. Report at least one of the outcomes: MACE, CV death, ST,
MI, stroke and major bleeding.
2.4. Exclusion criteria
Studies that did not meet the above criteria were excluded.
2.5. Data abstraction
After identifying all relevant articles, we extracted charac-
teristics of the study like (author, year, design, duration,
sample size, patient population, and genotype characteristics)Relative Risk of MACE: CYP2C1
Model Statistics for each study E
Risk
ratio 
Lower
limit
Upper
limit p.Value
C
SHULDINER
MEGA T 38
PARE CURE
MALE K
SIMON
TRENK
COLLETE
WALLENTINE
BHATT
ANDERSON
WORRALL
SIBBING
GIUSTI
Yamamoto
2.063 1.069 3.934 0.031 14
1.493 1.061 2.100 0.021 46/
0.842 0.626 1.131 0.253 52/
0.800 0.099 6.488 0.834 1/
0.875 0.683 1.120 0.289 74/
0.593 0.224 1.570 0.293 5/2
3.474 1.675 7.206 0.001 15
1.137 0.947 1.365 0.170 149/
1.294 0.940 1.782 0.114 54/
1.387 0.998 1.926 0.051 48/
2.222 0.683 7.232 0.185 4/
1.228 0.906 1.665 0.185 56/
2.277 1.117 4.644 0.024 15/
6.460 0.368 113.538 0.202 5/
Random 1.283 1.065 1.547 0.009
Relative Risk of CV Death: CYP2C
Risk
ratio 
Lower
limit
Upper
limit p.Value
CYP
B
Study name Statistics for each study Even
MEGAT 38 
MALEK 0.773
COLLETE 5.096
GIUSTI 2.657
Yamamoto 1.762
Fixed 3.212
1.631
0.038
0.469
1.062
0.074
1.655
17.791
15.520
55.345
6.649
42.147
6.233
0.006
0.866
0.181
0.037
0.727
0.001
8:395
0/21
2/73
10/247
1/62
Model
5.387
Study name
Fig. 2 e CYP2C19*2 analysis e major adverse cardiovascular evand outcomes like (MACE, CV death, MI, ST, stroke, major
bleeding complications and follow-up percentage). Two
reviewers independently extracted data and assessed
outcomes. The inter-rater agreement was 90%, and disagree-
ments were resolved by consensus.2.6. Quality assessment
All the trials reported adequate concealment of the random-
ized treatment sequence. In all studies, follow-up was more
than 90% complete.2.7. Statistical analysis
Combined relative risks (RR) across all the studies with 95%
confidence intervals (CI) were computed for each endpoint by
using the Comprehensive Meta-Analysis software package
(version CM 2.2, Biostat, Englewood, NJ). Heterogeneity of the
studies was assessed for each endpoint (Table 2). Those
studies that were homogenous for an endpoint were analyzed
by the ManteleHaenszel fixed effect model, while those9 Norm (A) and Variants (B)
vents/Total Risk ratio and 95% Cl
YP
B
CYP
A
/67 16/158
395 83/1064
651 179/1886
21 5/84
617 214/1561
45 19/552
/73 11/186
1388 332/3516
720 99/1708
350 89/900
24 6/80
680 121/1805
247 14/525
62 0/36
0.01 0.1 1 10 100
Favours variant Favours Normal
19 Norm (A) and Variants (B)
CYP
A
ts /Total
4/1064
2/84
1/186
8/525
0/36
Risk ratio and 95% CI
0.01 0.1 1 10 100
Favours Variant Favours Normal
ents (upper panel) and cardiovascular death (lower panel).
i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 3 4 1e3 5 2 345studies that were heterogeneous for an endpoint were
analyzed by the random effect model. A two-sided alpha error
of <0.05 was considered to be statistically significant. The
inverse variance method was used for study weighting.
Potential publication biases were assessed by the funnel plot
method and Egers test. Sensitivity, specificity, and the positive
and negative predictive values of genetic testing were
computed for each endpoint.3. Results
3.1. Literature search for CYP2C19*2 polymorphism
A total of 107 articles were identified of which 40 were
potentially relevant studies and screened for retrieval. After
title and abstract evaluation, 19 studies were excluded and 21
studies were retrieved for a more detailed screening. Out of
these 21 studies 7 studies were excluded and fourteen trials
were included for final analysis [Fig. 1]. Among excluded seven
studies, 3 studies were excluded, as they have demonstrated
genotype polymorphism co-relation with platelet reactivity
and no clinical outcomes assessed,20e22 while other 3 studies
were excluded as they have either compared the different
genotype (CYP2C19*17)23 or no clinical outcomes were evalu-
ated.24,25 Additionally, CLARITY TIMI 28 genomic study was
excluded as data was not extractable.26 Thus, fourteen trials
were included in the final analysis.26e40Relative Risk of MI: CYP2C19 Norm
Relative Risk of Stent Thrombosis in All Studie
Model Study name
Risk
ratio
Risk
ratio
MEGA T 38
MALEK
COLLETE
WALLENTINE
SIBBING
GIUSTI
Lower
limit
Upper
limit p-Value Var
Lower
limit
Upper
limit p-Value
CYP
B
Statistics for each study Even
Model
Fixed
3.380
0.489
1.659
0.865
1.449
1.142
1.697
8.499
274.872
17.004
2.524
9.922
5.527
3.414 0.000
0.022 13/
0.007
0.153
0.005
0.129
0.010
10/
21/
8/
1/
10/1.344
11.591
5.311
1.478
3.792
2.512
2.407
Study name Statistics for each study Event
MEGA T 38
MALEK
COLLETE
ANDERSON
SIBBING
Yamamoto
Fixed
1.347 0.938 1.933 0.106 40/395
1/21
10/73
42/350
48/680
2/62
0.799
0.004
0.045
0.408
0.483
0.002
12.180
11.261
2.058
1.592
59.521
1.657
0.146
1.601
1.008
0.828
0.145
1.122
1.333
4.247
1.440
1.148
2.937
1.363
Fig. 3 e CYP2C19*2 analysis e myocardial infarction (3.2. Literature search for ABCB1 polymorphism
A total of three studies identified which also looked in to
ABCB1 polymorphism data and included in our meta-analysis
comparing the effect of clopidogrel in CAD patients with or
without ABCB1 polymorphism.31,34,41
3.3. Overview of study and patient characteristics
Study design was either RCT or post hoc analysis of RCT,
comparison of clinical outcomes between a CYP2C19*2 or
ABCB1 carrier with non-carrier in CAD patients on clopidogrel
treatment. The characteristics of included trials are
mentioned in Table 1. For simplicity, patient population was
categorized as CYP2C19*2 carrier (defined as a variant) group
who are either heterozygous (has at least one loss of *2 func-
tional allele) or homozygous (has two loss of *2 functional
alleles). Patients were categorized in CYP2C19*2 non-carrier
(defined as normal) who are either carrying wild type (*1/*1)
or none *2 alleles. Similarly, for ABCB1 polymorphism patient
population was categorized in ABCB1 carrier (CT/TT) and
ABCB1 non-carrier (CC).
3.4. Endpoints
All fourteen studies included in meta-analysis had MACE as
a primary endpoint. Out of fourteen, six studies28,30,33,34,38,39
included in the meta-analysis had stent thrombosis (ST) as (A) and variants (B)
s: CYP2C19 Normals vs Variants
iant Normal
CYP
A
ts/Total Risk ratio and 95% CI
0.01 0.1 1 10 100
247 11/525
680
934
61
21
375 8/1014
0/84
4/162
35/2300
7/1805
s/Total Risk ratio and 95% CI
80/1064
3/84
6/186
75/900
111/1805
0/36
0.01
Favours Variant Favours Normal
Favours Variant   Favours Normal
0.1 1 10 100
upper panel) and stent thrombosis (lower panel).
i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1e3 5 2346an endpoint, while thee studies evaluated major
bleeding28,29,34 and stroke28,38,40 as an endpoints. Outcomes
for all studies included in our analysis are given in Table 1.
3.5. Heterogeneity testing
Results of heterogeneity testing for both CYP2C19*2 and
ABCB1 polymorphisms are shown in Table 2. For heteroge-
neous outcomes random effect model and for homogenous
outcomes fixed effect model was used. Publication bias anal-
ysis revealed no evidence of bias except for MI and ST
(Table 2).
3.6. Clinical outcomes of CYP2C19*2 polymorphism
The trials included in this meta-analysis consisted of a total of
19,601 patients (CYP2C19*2 carrier group, n¼ 5540; non-carrier
group, n¼ 14,061). The results of current meta-analysis are
shown in Figs. 2e8.
3.6.1. Major adverse cardiovascular event (MACE)
Overall there were total of 1726 [8.8%] MACE of which 538
[9.71%] were in carrier group while 1188 [8.44%] in the non-
carrier group. There was a significant increase of MACE in
carrier group [RR: 1.28, CI: 1.06e1.54; p¼ 0.009] [Fig. 2].
3.6.2. Cardiovascular (CV) death
There were a total of 36 [17.54%] cardiovascular deaths of
which 21 [2.63%] were in carrier group while 15 [0.79%] in the
non-carrier group. The risk of cardiovascular mortality was
higher in carrier groups than non-carrier group [RR: 3.21, CI:
1.65e6.23; p¼ 0.001] [Fig. 2].Relative Risk of Stroke: CYP2
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A total of 418 [7.39%] MI events occurred of which 143 [9.04%]
were in carrier group while 275 [6.74%] in the non-carrier
group. There was increase in MI events [RR: 1.36, CI:
1.12e1.65; p¼ 0.002] in carrier group compared to non-carrier
group [Fig. 3].
3.6.4. Stent thrombosis (ST)
This includes a total of definite, probable and possible stent
thrombosis. Incidence of ST was a total of 128 [1.56%]; out of
which 63 [2.72%] were in carrier group while 65 [1.10%] in the
non-carrier group. The risk of ST was significantly higher in
carrier groups than non-carrier group [RR: 2.41, CI: 1.69e3.41;
p< 0.001] [Fig. 3].
3.6.5. Stroke
Stroke outcome occurred only in 12 [0.29%] out of 4042
patients. The risk of stroke was also significantly higher in
carrier group versus non-carrier group [RR: 4.13, CI:
1.16e14.71; p¼ 0.029] [Fig. 4].
3.6.6. Major bleeding
A total of 626 [5.54%] bleeding events occurred of which 175
[5.57%] were in Carrier group while 451 [5.53%] in the non-
carrier group. Bleeding events did not differ between the two
groups [RR: 1.02, CI: 0.86e1.20; p¼ 0.84] [Fig. 4].
3.7. Subgroup analysis of CYP2C19*2 polymorphism
3.7.1. Major adverse cardiovascular event (MACE)
There was a significant increase in incidence of MACE in
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i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 3 4 1e3 5 2 347sub-groups {stable CAD patients undergoing PCI [RR: 1.34, CI:
1.02e1.76; p¼ 0.037], ACS patients [RR: 1.21, CI: 0.91e1.60;
p¼ 0.178] and patients undergoing PCI with DES [RR: 1.53, CI:
1.03e2.27; p¼ 0.035]} [Fig. 5].
3.7.2. Myocardial infarction (MI)
There was a significant increase of MI events in carrier group
in ACS patients [RR: 1.98, CI: 0.84e4.67; p¼ 0.118] but no
significant increase in MI events in carrier group in patients
undergoing PCI with DES [RR: 1.56, CI: 0.97e2.53; p¼ 0.067]
[Fig. 6].
3.7.3. Stent thrombosis (ST)
Stent thrombosis was significantly higher in carrier group of
patients undergoing PCI with DES [RR: 3.36, CI: 1.96e5.77;
p< 0.001] and ACS patients [RR: 2.17, CI: 1.42e3.33; p< 0.001]
[Fig. 7].3.8. Test parameters of CYP2C19*2 polymorphism
Test parameter analysis was done using 2  2 table. Genetic
assay for CYP2C19*2 polymorphism was found to have
sensitivity of (28e58%), specificity of (71e73%), negative
predictive value of (92e99%) and positive predictive value of
(3e10%) for various outcomes studied in this meta-analysis.
Test parameters for individual outcomes are given in Table 3.
3.9. Clinical outcomes of ABCB1 polymorphism
The trials included in this meta-analysis consisted of a total of
8758 patients (non-carrier group, n¼ 6384; carrier group,
n¼ 2374). The results of ABCB1-C3435T polymorphism
summarized in Fig. 5. Overall there were a total of 930 [10.61%]
MACE of which 274 [11.54%] were in carrier (CT/TT) group
while 656 [10.27%] in the non-carrier (CC) group. This
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i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1e3 5 2348difference between the two groups was not statistically
significant [RR: 1.13, CI: 0.99e1.29; p¼ 0.06] [Fig. 8]. Similar
results were obtained for ST [RR: 0.88, CI: 0.52e1.47; p¼ 0.63]
and major bleeding events [RR: 1.04, CI: 0.87e1.25; p¼ 0.62]
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i n d i a n h e a r t j o u rn a l 6 4 ( 2 0 1 2 ) 3 4 1e3 5 2 3492011. This pooled analysis is different from previous meta-
analysis,42e45 as we assessed not only the association but also
the CYP2C19*2 genetic testing parameters for individual
outcomes. We also analyzed the role of ABCB1 polymorphism
in clopidogrel non-responsiveness and included separate sub-
analysis of three different patient populations to identify the
population at risk.
Results of our analysis show that CYP2C19*2 poly-
morphism is associated with significantly increased relative
risk of MACE (1.28 fold), MI (1.3 fold), CVS death (3 fold), ST (2.4Table 3 e Test parameters of CYP2C19*2 polymorphism.
All studies
of CYP219*2
MACE CVS deaths MI ST Major
bleeding
Sensitivity % 31 58 34 43 28
Specificity % 72 71 73 73 72
NPV % 92 99 93 98 94
PPV % 10 3 9 4 6
[MACE¼Major Adverse Cardiovascular Event, CV¼Cardiovascular
and MI¼Myocardial Infarction, ST¼ Stent Thrombosis.]fold) and stroke (4 fold) without any decrease or increase in
the incidence of bleeding events. Moreover, stable patients
undergoing elective PCI also have significantly increased risk
for MACE (1.3 fold) with CYP2C19*2 polymorphism carrier
state. Additionally, it shows ABCB1 polymorphism is not
associated with increased incidence of MACE or ST.
Majority of stent thrombosis occur early (<30 days) and
according to previous reports incidences are approximately
1% that causes serious consequences like MI, CVS deaths and
strokes.46 According to our analysis, compared to normal
genotype, CYP2C19*2 polymorphism was associated with
higher incidence of stent thrombosis, MI, CVS deaths and
strokes. Overall, we found higher risk of ST (2.4 fold) as
compared to MACE (1.28 fold). This could be due to the fact
that MACE was reported in 14 studies while ST was reported
by only six studies with wide confidence intervals.
Based on our data, CYP2C19*2 polymorphism genotyping
has around 10% positive predictive value for almost each
adverse outcomes (MI, MACE, CVS deaths etc.) which suggest
that genotyping has no predictive value to detect studied
outcomes. On the other hand, normal CYP2C19 had a very
high (90e100%) negative predictive value for almost each
adverse outcome. Thus, patients without CYP2C19*2
i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 3 4 1e3 5 2350polymorphism are at very low risk of having an adverse event
while in case of polymorphisms, the negative outcome does
not seem to be predictable. This is true despite that the overall
RR values indicate higher risks in this patient group. Thus, it is
reasonable to think that there are other (unknown?) factors
that play the major role in the negative outcomes in
CYP2C19*2 polymorphism group of patients. This finding
indicates the potential role genotype testing may play in
evaluating genetically non-modifiable factors responsible for
clopidogrel non-responsiveness in patient with recurrent
ischemic events. However, due to the poor sensitivity and low
positive predictive value, routine genetic testing cannot be
recommended at present.
Our data also shows that ABCB1 polymorphism has no
clinical role in clopidogrel non-responsiveness in patient
undergoing PCI or patients with ACS. Although, this data only
compares, the 3435C/ T heterozygous/homozygous variant
(includes CT/TT) to normal (CC) while data comparing
homozygous variant (TT) to normal (CC) is not known and is
a subject to be evaluated in future study.
Subgroup analysis of stable CAD patients undergoing
elective PCI shows higher incidence of MACE (1.3 fold) in
variant group compared with normal group, which contra-
dicts the conclusion drawn from CHARISMA genomic sub-
study that indicated no association with ischemic outcomes
in CYP2C19*2 heterozygotes.35 As previously mentioned, high
on treatment platelet reactivity (HTPR) is the patho-
physiologic phenomenon behind the development of recur-
rent ischemic events in ACS patients or patients undergoing
PCI.47 Apart from pharmacogenetic polymorphism, other
factors also contributes to HTPR are non-compliance, under-
dosing, drugedrug interactions, co-morbidities (diabetes
mellitus, abnormal renal function, hyperlipidemia, obesity)
active smoking, clinical presentation, and procedural
complexities.7 According to initial data published in GRAV-
ITAS trial (Price et al) shows that even after adjusting clopi-
dogrel therapy (maintenance dose 150 mg), based on
persistent HTPR assessed by platelet function test, did not
result in change in clinical outcomes and persistent HTPRwas
attributed to non-modifiable risk factors like clinical presen-
tation, procedural characteristics and genetic poly-
morphism.48 Therefore, combining platelet function testing to
identify the HTPR followed by genotyping to identify
CYP2C19*2 polymorphism may give us guidance to use alter-
nate anti-platelets like prasugrel49 or ticagrelor.33
Overall, the prevalence of laboratory-defined clopidogrel
non-responsiveness has been estimated at 21e26%.50 Clinical
implications to clopidogrel non-responsiveness of CYP2C19*2
polymorphism are obvious since significant number of pop-
ulation has at least one loss-of-function CYP2C19 allele:
z30e50% of Asians, 11e16% of Caucasians, and 14e25% of
African-Americans.51 Recently, FDA issued black box warning
regarding use of clopidogrel in poor metabolizers but recom-
mended against routine genotyping in patients on clopidogrel
therapy.52 Our meta-analysis indicates that CYP2C19*2 poly-
morphism results in significantly increased risk of cardio-
vascular events like MI, ST and CV deaths. Therefore it is
imperative to have clinical trial designed to evaluate clinical
benefit of personalizing antiplatelet therapy based on geno-
typing and platelet function test.As with any meta-analysis, one of the limitations of our
study is the difference in the definitions of the endpoints in
the component trials, such as the definition of MACE, MI and
CV death was different in various studies. Also, there was also
heterogeneity in the study population, follows up duration,
clopidogrel therapy protocol. Similarly, baseline characteris-
tics between the two groups cannot be compared completely
in most meta-analyses because of differences in the study
protocols across the component trials. Also, there is a poten-
tial for publication bias but the trials in our analysis had
different results and it should reduce this potential risk.
Moreover, publication bias analysis was negative for all
outcomes except for MI and ST indicating robustness of our
results.5. Conclusion
In CAD patients on clopidogrel therapy, CYP2C19*2 poly-
morphism is associated with significantly increased adverse
cardiovascular events. However, due to the low positive
predictive value, routine genetic testing cannot be recom-
mended at present and should not be performed.Funding/Support
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